13F Holdings
中文EN

LONA LeonaBio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1620463 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-313.6%
TTM EPS YoY-129.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-729.0%
ROA-457.7%
ROIC (approx.)-3,861.7%
Asset turnover—

Leverage & solvency

Liabilities / assets58.0%
Debt / equity0.00x
Current ratio4.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.49x
Accruals ratio-234.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$17.50M$70.68M$93.79M$61.46M$42.79M
SG&A expense$16.68M$26.09M$33.30M$32.55M$21.23M
Operating income-$102.27M-$100.90M-$125.47M-$104.02M-$64.02M
Interest expense————$3,000
Pretax income-$105.61M-$96.91M-$117.44M-$95.78M-$54.96M
Income tax$0————
Net income-$105.61M-$96.94M-$117.67M-$95.64M-$54.85M
EBITDA-$101.29M-$99.93M-$124.50M-$103.17M-$63.54M
EPS (basic)-24.70-25.19-3.09-2.53-1.49
EPS (diluted)-24.70-25.19-3.09-2.53-1.49
Weighted avg. shares (diluted)4.28M3.85M38.02M37.73M36.92M
Balance sheet
Cash & equivalents$69.28M$48.44M$90.58M$95.97M$110.54M
Short-term investments$19.05M$2.84M$56.84M$104.38M$143.22M
Current assets$89.46M$54.84M$154.73M$207.53M$260.80M
PP&E, net$1.47M$2.44M$3.39M$4.05M$3.76M
Total assets$92.15M$58.78M$160.25M$258.15M$332.01M
Current liabilities$47.50M$13.13M$28.84M$21.43M$9.29M
Total liabilities$64.36M$13.94M$30.06M$23.02M$10.92M
Shareholders' equity$27.79M$44.84M$130.19M$235.14M$321.08M
Shares outstanding9.34M3.90M38.17M37.88M37.38M
Cash flow statement
Operating cash flow-$45.73M-$97.17M-$100.75M-$72.47M-$43.10M
Capital expenditure—$33,000$304,000$1.14M$1.57M
Free cash flow—-$97.20M-$101.06M-$73.61M-$44.67M
Investing cash flow-$15.89M$54.83M$95.09M$57.66M-$4.08M
Financing cash flow$82.46M$194,000$493,000$654,000$97.09M
Depreciation & amortization$972,000$970,000$969,000$845,000$479,000
Stock-based compensation$6.10M$11.05M$10.62M$10.61M$4.62M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.